FDA 510(k) Path Advances: Intelligent Bio Solutions Starts Multi-Site Codeine Screening Study
INBS sits 19% above its 52-week low of $2.27.
Summary
Intelligent Bio Solutions has initiated a multi-site Method Comparison Study to support its FDA 510(k) submission for the Intelligent Fingerprinting Drug Screening System for codeine. This critical step follows previous progress towards FDA clearance, including an initial clinical cut-off study and penetration testing, and was also reported in an 8-K filing today. The study involves 135 donor participants and 9 operators to validate real-world performance and ease of use. Successful completion of this study is vital for obtaining FDA 510(k) clearance, which is crucial for commercializing the product and addressing the company's recent going concern warning. Enrollment and data collection are expected to be completed by the end of July 2026.
At the time of this announcement, INBS was trading at $2.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.9M. The 52-week trading range was $2.27 to $24.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.